WCLC 2025 - Posters & ePosters-EP.12.28 Real-World Clinical Outcomes in Chinese Patients With Advanced EGFR-Mutated NSCLC on First-Line Third-Generation EGFR-TKIs Treatment

EP.12.28 Real-World Clinical Outcomes in Chinese Patients With Advanced EGFR-Mutated NSCLC on First-Line Third-Generation EGFR-TKIs Treatment

Back to course

Pdf Summary

This retrospective study assessed real-world clinical outcomes in 169 Chinese patients with advanced non-small cell lung cancer (aNSCLC) harboring epidermal growth factor receptor mutations (EGFRm), treated first-line with third-generation EGFR tyrosine kinase inhibitors (3G EGFR-TKIs), specifically aumolertinib (60 patients) and osimertinib (109 patients), between December 2019 and July 2024. Median ages were similar (69 years for aumolertinib; 70 for osimertinib), with most patients having adenocarcinoma histology and varying EGFR mutation subtypes (exon 19 deletion, L858R, others). Brain metastases were present in a subset.<br /><br />At median follow-up of 17.6 months for aumolertinib and 16.6 months for osimertinib, progression-free survival (PFS) and response outcomes were analyzed. The objective response rate (ORR) was higher with aumolertinib (75.0%) than osimertinib (57.8%), while disease control rates were comparable at ~96.7% and 94.5%. Median PFS was not reached for aumolertinib but was 26.5 months for osimertinib. The 18-month PFS rate favored aumolertinib (80% vs. 70%). Progressions occurred in 11 and 47 patients, respectively. Adverse events (AEs) of any grade were reported in 31.7% (aumolertinib) and 38.5% (osimertinib) with grade 3 or higher AEs in 6.7% and 13.8%, respectively.<br /><br />The study highlights that, unlike phase 3 clinical trials with more selective populations, the Chinese patients in this real-world setting had more complex baseline characteristics but still experienced favorable outcomes with 3G EGFR-TKIs. These findings provide valuable clinical practice insights, supporting the use of aumolertinib and osimertinib as effective and generally well-tolerated first-line therapies for EGFR-mutated aNSCLC in China.

Asset Subtitle

Xinlin Mu

Meta Tag

Speaker Xinlin Mu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

advanced non-small cell lung cancer

EGFR mutations

third-generation EGFR-TKIs

aumolertinib

osimertinib

progression-free survival

objective response rate

Chinese patients

real-world study

adverse events